Product Code: 05-PHARM-PANEL-26
From £475.00 Early Bird
Early Bird Deadline: 31/01/2026
Deadline to order: 28/02/2026
Pharmacogenetic panel testing of markers for drug response and efficacy (Germline DNA).
A panel of clinically relevant variants in the CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP3A5, DPYD, fVl, HLA-B, SLCO1B1, TPMT, UGT1A1 and VKORC1 genes. CYP3A4 and NUDT15 are also included. If you undertake testing restricted to DYPD, or UGT1A1, then we also have a standalone EQA scheme for these pharmacogenetics markers.
CNV, MLPA, NGS, Panel testing, PCR based, Sanger sequencing
English, German
DNA (in TE Buffer)
Yes
June 2026
June - August 2026
December 2026 - January 2027
You can complete purchase on our secure partner site.
The scheme is designed to assess the analytical process (genotyping), and reporting (biological and clinical interpretation of the test result) including the overall report layout, content and clerical accuracy.
To account for differing panel compositions, variants outside the stated scope of an individual laboratory’s panel will be excluded from their assessment.
More information, including the EMQN validation panel, is available on request and complete details will be provided in the scheme instructions.
Three mock clinical cases with matching samples will be provided. Approximately 3-4µg DNA per sample is provided. Complete information will be available in the scheme instructions.
PLEASE NOTE: In previous years we have guaranteed at least one DPYD relevant clinical case scenario. Due to the provision of the new pilot DPYD and UGT1A1 EQA scheme, this will no longer be the case.
Participants will receive an individual report including educational advice and a scheme report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics allowing participants to benchmark their results.
Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.
Participants are expected to test samples according to their routine strategy, to return a clinical report and to complete the data collection form.
No restrictions on number of participants. Open to laboratories from ALL countries (note: some restrictions may apply due to sanctions, delivery network exceptions, restrictions on importation etc).
added wishlist!
View Wishlist
View Wishlist
Express your interest in ''.
